Country: Ísrael
Tungumál: enska
Heimild: Ministry of Health
ALUMINIUM CHLOROHYDROXIDE COMPLEX SOLUTION; METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE; SULFUR
PFIZER PFE PHARMACEUTICALS ISRAEL LTD
D10AA02
LOTION
METHYLPREDNISOLONE ACETATE 2.5 MG/ML; NEOMYCIN SULFATE 2.5 MG/ML; SULFUR 50 MG/ML; ALUMINIUM CHLOROHYDROXIDE COMPLEX SOLUTION 200 MG/ML
DERMAL
Required
PATHEON INC. WHITBY OPERATIONS, CANADA
METHYLPREDNISOLONE
METHYLPREDNISOLONE
Acne.
2014-01-31
Pfleet 2020-0061264 2 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only NEO-MEDROL ACNE LOTION ® ACTIVE INGREDIENTS Each ml contains: methylprednisolone acetate 2.5 mg neomycin sulphate 2.5 mg sulfidal (sulfur) 50.0 mg aluminum chlorhydroxide complex solution 200 mg For a list of inactive ingredients and allergens in this preparation, see section 6 "Further information”. READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? For treating acne. THERAPEUTIC GROUP: Methylprednisolone acetate – synthetic glucocorticoid. Neomycin sulphate – antibiotic from the aminoglycoside group. Sulfur – mineral (sulfur). Aluminum chlorohydrate - mineral. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: • you are sensitive (allergic) to the active ingredients or any of the additional ingredients contained in the medicine (listed in section 6). • you suffer from herpes simplex, cowpox, chicken pox, tuberculosis of the skin or any other skin infection which does not respond to neomycin. DO NOT USE THE MEDICINE WITHOUT CONSULTING A DOCTOR BEFORE STARTING TREATMENT: • If you are pregnant. SPECIAL WARNINGS REGARDING USE OF THE MEDICINE • If sensitivity or irritation develop, stop using the preparation. • Do not use the preparation on broad skin areas, unless recommended by the attending doctor. • If previously non-existent local inflammation develops during use of the preparation, stop using the preparation. • Do not allow the preparation to come into contact with the eyes or ears. In the event of contact, wash immediately with water. • Special caution is required when Lestu allt skjalið
Neo-Medrol Acne Lotion CC LPD 210620 1 Pfleet 2020-0061264 PRESCRIBING INFORMATION NAME OF THE MEDICINAL PRODUCT NEO-MEDROL ® ACNE LOTION QUALITATIVE AND QUANTITATIVE COMPOSITION NEO-MEDROL Acne Lotion contains Aluminum Chlorhydroxide Complex Solution 200 mg/ml, Sulfidal (Sulfur) 50.0 mg/ml, Methylprednisolone Acetate 2.5 mg/ml, Neomycin Sulfate 2.5 mg/ml EXCIPIENTS WITH KNOWN EFFECT: butyl hydroxybenzoate 0.3% and methyl hydroxybenzoate 0.2%. PHARMACEUTICAL FORM Lotion CLINICAL PARTICULARS THERAPEUTIC INDICATIONS NEO-MEDROL Acne Lotion is used for the treatment of acne. CONTRAINDICATIONS In tuberculosis of the skin, herpes simplex, vaccinia, varicella and in other cutaneous infections which do not respond to neomycin. Hypersensitivity to the active substance or to any of the excipients listed in section "PHARMACEUTICAL PARTICULARS" PRECAUTIONS Avoid contact with eyes. If signs of irritation or sensitivity develop, application should be discontinued. As with any antibiotic containing product, overgrowth by resistant organisms may occur, particularly monilia. If this occurs, discontinue treatment and institute appropriate measures. Articles in current medical literature indicate an increase in the incidence of patients allergic to neomycin. The possibility of such a reaction should be borne in mind. Neo-Medrol Acne Lotion CC LPD 210620 Pfleet 2020-0061264 2 If extensive areas are treated or if the occlusion technique is used, the possibility exists of increased absorption of the corticosteroid and suitable precautions should be taken. The prolonged use of antibiotic-containing preparations may result in overgrowth of nonsusceptible organisms, particularly fungi. If new infections appear during treatment, appropriate therapy should be instituted. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine. Since concurrent administration of these agents results in a mutual inhibition of metabolism, it is possible that convulsions and other adverse events associated with the individual Lestu allt skjalið